Shareholders might have noticed that Insmed Incorporated (NASDAQ:INSM) filed its quarterly result this time last week. The early response was not positive, with shares down 10.0% to US$65.08 in the past week. Insmed reported revenues of US$93m, in line with expectations, but it unfortunately also reported (statutory) losses of US$1.42 per share, which were slightly larger than expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NasdaqGS:INSM Earnings and Revenue Growth May 11th 2025

Taking into account the latest results, the consensus forecast from Insmed's 16 analysts is for revenues of US$467.6m in 2025. This reflects a substantial 23% improvement in revenue compared to the last 12 months. The loss per share is expected to ameliorate slightly, reducing to US$5.30. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$467.8m and losses of US$5.37 per share in 2025.

Check out our latest analysis for Insmed

The consensus price target was unchanged at US$96.89, suggesting that the business - losses and all - is executing in line with estimates. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Insmed, with the most bullish analyst valuing it at US$109 and the most bearish at US$89.00 per share. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Insmed's growth to accelerate, with the forecast 31% annualised growth to the end of 2025 ranking favourably alongside historical growth of 19% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Insmed to grow faster than the wider industry.

Story Continues

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Insmed going out to 2027, and you can see them free on our platform here..

That said, it's still necessary to consider the ever-present spectre of investment risk.  We've identified 2 warning signs  with Insmed , and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments